Esperion Therapeutics Net Income

Esperion Therapeutics (ESPR) currently reports a net income of $510K as of March 2026. That compares with $-150M in the prior-year period — up 100.3% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Esperion Therapeutics's net income history and peer comparisons.

Esperion Therapeutics's net income increased from $-150M to $510K — a 100.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Esperion Therapeutics's net income of $510K is lower than the Healthcare sector average of $17B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Esperion Therapeutics reported $510K in net income as of March 2026. That compares with $-150M in the prior-year period — up 100.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $510K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Esperion Therapeutics, and consider following ESPR for alerts when major investors trade the stock.